Over the next three years, Immunovia and its partners will use the firm's Immray PanCan-d assay to screen 6,000 diabetes patients for pancreatic cancer.
One firm, Exosome Diagnostics, is working to streamline payor coverage for a commercial test, and researchers are simultaneously developing promising ways to isolate exosomes.
Given the high yield of miRNA markers they were able to isolate, the researchers believe the approach could be commercialized for routine cancer testing.
The team found that telomere fusions in pancreatic cells can act as potential predictive biomarkers for invasive cancer and high grade dysplasia in patients.
The test has already shown in large retrospective clinical studies that it can achieve an accuracy of 96 percent for early stage detection, according to Immunovia's CEO.
The SEK4.9 million ($585,000) grant will support development studies for the firm's Immray PanCan-d blood based test for the early detection of pancreatic cancer.
The initiative's four research projects will use use genetic and other technologies to detect and treat cancer at its earliest stages.
The seven-gene NGS-based test is available for patients who are found to have pancreatic cysts, and can help physicians decide whether to remove them.
Asia Genomics will make CellMax's tests, including the CellMax-DNA Genetic Cancer Risk Test Assure and the CellMax-CRC Protect Test, available immediately.
The assay employs nanoplasmonics and protein-signal multiplexing in taking aim at early clinical detection of pancreatic ductal adenocarcinoma.